Erratum: Attention-deficit/hyperactivity disorder: Are we helping or harming? (BMJ (Online) (2013) 347 (f6172) DOI: 10.1136/bmj.f6172);Attention-deficit/hyperactivity disorder: Are we helping or harming?

BMJ (Online)

Volumn 347, Issue , 2013, Pages

  Thomas, Rae ^a   Mitchell, Geoffrey K ^b   Batstra, Laura ^c  

^a BOND UNIVERSITY   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE DERIVATIVE; METHYLPHENIDATE; RISPERIDONE;

ATTENTION DEFICIT DISORDER; BODY MASS; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC ERROR; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DSM-5; HUMAN; MEDICAL PRACTICE; ONSET AGE; PATIENT ADVOCACY; PATIENT SAFETY; PRESCRIPTION; PRIORITY JOURNAL; RESEARCH DIAGNOSTIC CRITERIA; REVIEW; RISK ASSESSMENT; SIDE EFFECT; VULNERABLE POPULATION; WAIST CIRCUMFERENCE; WEIGHT GAIN;

EID: 84888156773     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.g4377     Document Type: Erratum

References (61)

1. Fayyad J, De Graaf R, Kessler R, Alonso J, Angermeyer M, Demyttenaere K, et al. Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br J Psychiatry 2007;190:402-9.
2. De Graaf R, Kessler R, Fayyad J, ten Have M, Alonso J, Angermeyer M, et al. The prevalence and effects of adult attention-deficit/ hyperactivity disorder (ADHD) on the performance of workers; Results form the WHO world mental health survey initiative. Occup Environ Med 2008;65:835-42.
3. Centers for Disease Control and Prevention. Increasing prevalence of parent-reported attention-deficit/hyperactivity disorder among children - United States, 2003 and 2007. MMWR 2010;59:1439-43.
4. Döpfner M, Breuer D, Wille N, Erhart M, Ravens-Sieberer U, the BELLA Study Group. How often do children meet ICD-10/DSM-IV criteria of attention deficit-/hyperactivity disorder? Parent-based prevalence rates in a national sample - results of the BELLA study. Eur Child Adolesc Psychiatry 2008;17:59-70.
5. National Institute for Health and Clinical Excellence. Attention deficit hyperactivity disorder: diagnosis and management of ADHD in children, young people and adults. NICE clinical guideline 72. 2013. guidance.nice.org.uk/cg72
6. American Academy of Pediatrics. ADHD: clinical practice guideline for the diagnosis. evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics 2011;128:1007-22.
7. National Health and Medical Research Council. Clinical practice points on the diagnosis, assessment and management of attention deficit hyperactivity disorder in children and adolescents. Commonwealth of Australia, 2012.
8. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. American Psychiatric Association, 2013. www.dsm5.org/Documents/ADHD%20Fact%20Sheet.pdf.
9. Centers for Disease Control and Prevention. Mental health surveillance among children - United States, 2005-2011. MMWR 2013;62(suppl 2):1-35.
10. Biederman J, Mick E, Faraone SV, Braaten E, Doyle A, Spencer T, et al. Influence of gender on attention deficit hyperactivity disorder in children referred to a psychiatric clinic. Am J Psychiatry 2002;159:36-42.
11. Robison LM, Skaer TL, Sclar DA, Galin RS. Is attention deficit hyperactivity disorder increasing among girls in the US? Trends in diagnosis and the prescribing of stimulants. CNS Drugs 2002;16:129-37.
12. Garfield CF, Dorsey ER, Zhu S, Huskamp HA, Conti R, Dusetzina SB, et al. Trends in attention deficit hyperactivity disorder ambulatory diagnosis and medical treatment in the United States, 2000-2010. American Pediatr 2012;12:1106.
13. Fischer ER, Heiner J, Kalverdijk LJ, Prins PJM, Swaab-Barneveld JT, eds. Multidisciplinaire richtlijn ADHD: Richtlijn voor de diagnostiek en behandeling van ADHD bij kinderen en jeugdigen [Dutch guideline for diagnosing and treating ADHD in children and youth]. Trimbosinstituut, 2005.
14. McGee R, Prior M, Williams S, Smart DAS. The long-term significance of teacher rated hyperactivity and reading ability in childhood: findings from two longitudinal studies. J Child Psychol Psychiatry 2002;43:1004-17.
15. Hoza B. Peer functioning in children with ADHD. Ambul Pediatr 2007;7:101-6.
16. Kang JH, Lin HC, Chung SD. Attention-deficit/hyperactivity disorder increased the risk of injury: a population-based follow-up study. Acta Paediatrica 2013;102:640-3.
17. Barkley R. Major life activity and health outcomes associated with Attention-Deficit/Hyperactivity Disorder. J Clin Psychiatr 2002;63(suppl 12):10-5.
18. Dalsgaard S, Mortensen PB, Frydenberg M, Thomsen PH. Long-term criminal outcome of children with attention deficit hyperactivity disorder. Criminal Behaviour and Mental Health 2013;23:86-98.
19. Molina B, We P. Substance use, substance abuse and LD among adolescents with a childhood history of ADHD. J Learning Disabil 202;34:333-42.
20. Jerome L, Segal A, Habinski L. What we know about ADHD and driving risk: Literature review, meta-analysis and critique. J Can Adolesc Psychiatry 2006;15:105-25.
21. Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry 2007;164:942-8.
22. Wolraich ML, McKeown RE, Visser SN, Bard D, Cuffe S, Neas B, et al. The prevalence of ADHD: Its diagnosis and treatment in four school districts across two states. J Atten Dis 2012 Sep 5 [Epub ahead of print].
23. Evans WN, Morrill MS, Parente ST. Measuring inappropriate medical diagnosis and treatment in survey data: the case of ADHD among school-age children. J Health Econ 2010;29:657-73.
24. Morrow RL, Garland EJ, Wright JM, Maclure M, Taylor S, Dormuth CR. Influence of relative age on diagnosis and treatment of attention-deficit/ hyperactivity disorder in children. CMAJ 2012;184:755-62.
25. Stephenson CP, Karanges E, McGregor IS. Trends in the utilisation of psychotropic medications in Australia from 2000 to 2011. Aust NZ J Psychiatry 2013;47: 74-87.
26. McCarthy S, Wilton L, Murray ML, Hodgkins P, Asherson P, Wong CK. The epidemiology of pharmacologically treated attention deficit hyperactivity disorder (ADHD) in children, adolescents and adults in UK primary care. BMC Pediatrics 2012;12:78.
27. Zuvekas SH, Vitiello B. Stimulant medication use among US children: a twelve-year perspective. Am J Psychiatry 2012;169:160-6.
28. Hodgkins P, Sasané R, Meijer W. Pharmacologic treatment of attention-deficit/hyperactivity disorder in children: incidence, prevalence, and treatment patterns in the Netherlands. Clin Ther 2011;33:188-203.
29. Zwi M, Jones H, Thorgaard C, York A, Dennis J. Parent training interventions for attention deficit hyperactivity disorder (ADHD) in children aged 5 to 18 years. Cochrane Database Syst Rev 2011;12:CD003018.
30. Charach A, Dashti B, Carson P, Booker L, Lim CG, Lillie E, et al. Attention deficit hyperactivity disorder: effectiveness of treatment in at-risk preschoolers; long-term effectiveness in all ages; and variability in prevalence, diagnosis, and treatment. Comparative effectiveness review No 44. 2011. www.effectivehealthcare.ahrq.gov/reports/final.cfm.
31. Parker J, Wales G, Chalhoub N, Harpin V. The long-term outcomes of interventions for the management of attention deficit hyperactivity disorder in children and adolescents: a systematic review of randomized controlled trials. Psychol Res Behav Manag 2013;17:87-99.
32. Molina BS, Hinshaw SP, Swanson JM, Arnold LE, Vitiello B, Jensen PS, et al. The MTA at 8 years: prospective follow-up of children treated for combined-type ADHD in a multisite study. J Am Acad Child Adolesc Psychiatry 2009;48:484-500.
33. Batstra L, Frances A. Holding the line against diagnostic inflation. Psychother Psychosom 2012;81:5-10.
34. Thomas R, Doust J, Sanders S, Glasziou P. Worldwide prevalence of attention-deficit hyperactivity disorder: a systematic review. Paper presented at preventing overdiagnosis conference, 10-12 September 2013, Dartmouth USA.
35. Crone EA. Executive functions in adolescence: inferences from brain and behavior. Dev Science 2009;12:825-30.
36. Gordon M, Antshel K, Faraone S, Barkley R, Lewandowski L, Hudziak JJ, et al. Symptoms versus impairment: The case for respecting DSM-IV's criterion. J Atten Disord 2006;9:465-75.
37. Sonnby K, Aslund C, Leppert J, Nilsson KW. Symptoms of ADHD and depression in a large adolescent population: co-occurring symptoms and associations to experiences of sexual abuse. Nordic J Psychiatry 2011;65:315-22.
38. Alloway T, Elliott J, Holmes J. The prevalence of ADHD-like symptoms in a community sample. J Atten Disord 2010;14:52-6.
39. Lynch F, Mills C, Daly I, Fitzpatrick C. Challenging times: prevalence of psychiatric disorders and suicidal behaviours in Irish adolescents. J Adolesc 2006;29:555-73.
40. August GJ, Ostrander R, Bloomquist MJ. Attention deficit hyperactivity disorder: an epidemiological screening method. Am J Orthopsychiatry 1992;62:387-96.
41. Bruchmüller K, Margraf J, Schneider S. Is ADHD diagnosed in accord with diagnostic criteria? Overdiagnosis and influence of client gender on diagnosis. J Consult Clin Psychol 2012;80:128-38.
42. Cosgrove L, Krimsky S. A comparison of DSM-IV and DSM-5 panel members' financial associations with industry: a pernicious problem persists. PLoS Med 2012:9:3:e1001190.
43. Kravitz RL, Epstein RM, Feldman MD, Franz CE, Azari R, Wilkes MS, et al. Influence of patients' requests for direct-to-consumer advertised antidepressants: a randomized control trial. JAMA 2005;293:1995-2002.
44. Gilbert S, Wilson P, Watt I. Benefits and harms of direct to consumer advertising: a systematic review. Qual Saf Health Care 2005;14:246-50.
45. Mintzes B, Barer ML, Kravitz RL, Bassett K, Lexchin J, Kazanjian A, et al. How does direct-to-consumer advertising (DTCA) affect prescribing? A survey in primary care environments with and without legal DTCA. CMAJ 2003;169:405-12.
46. Mitchell J, Read J. Attention-deficit hyperactivity disorder, drug companies and the internet. Clin Child Psychol Psychiatry 2011;17:121-39.
47. CHADD. Professional baseball player Shane Victorino raises awareness of attention-deficit/hyperactivity disorder in young adults and adults through "own it" initiative. Press release, 26 September 2013 www.chadd.org/Portals/0/PDFs/Shane-Victorino-Own-It-Campaign-Press-Release-5-17- 12.PDF.
48. Everyday Health. Could you have ADHD? 2013. www.everydayhealth.com/ ownyouradhd.
49. CHADD. CHADD's Income and Expenditures (2008-2009). www.chadd.org/ Portals/0/PDFs/CHADD-income-sources-2009-November2009.pdf.
50. Foggo D. ADHD advice secretly paid for by drug companies. Telegraph 2005 Oct 9. www.telegraph.co.uk/news/uknews/1500215/ADHD-advice-secretly-paid-for-by- drugs-companies.html
51. Elder TE. The importance of relative standards in ADHD diagnoses: evidence based on exact birth dates. J Health Econ 2010;29:641-56.
52. Zima BT, Bussing R, Lingqu T, Tang L, Zhang L, Ettner S, et al. Quality of care for childhood attention deficit/hyperactivity disorder in a managed care Medicaid program. J Am Acad Child Adolesc Psychiatry 2010;49:1225-37.
53. Scheffler RM, Hinshaw SP, Modrek S, Levine P. The global market for ADHD medications. Health Aff 2007;26: 450-7.
54. Ruggiero S, Rafaniello C, Bravaccio C, Grimaldi G, Granato R, Pascotto A, et al. Safety of attention deficit/hyperactivity disorder medications in children: An intensive pharmacosurveillance monitoring study. J Child and Adolescent Psychopharm 2012;22:415-22.
55. Poulton AS, Melzer E, Tait PR, Garnett SP, Cowell CT, Baur LA, et al. Growth and pubertal development of adolescent boys on stimulant medication for attention deficit hyperactivity disorder. Med J Aust 2013;198:29-32.
56. Swanson J, Arnold LE, Kraemer H, Hechtman L, Molina B, Hinshaw S, et al. Evidence, interpretation, and qualification from multiple reports of long-term outcomes in the Multimodal Treatment Study of Children with ADHD (MTA): part I: executive summary. J Atten Disord 2008;12:4-14.
57. Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 2009;302:1765-73.
58. Walker JS, Coleman D, Lee J, Squire PN, Friesen BJ. Children's stigmatization of childhood depression and ADHD: magnitude and demographic variation in a national sample. J Am Acad Child Adolesc Psychiatry 2008;47:912-20.
59. Sayal K, Owen V, White K, Merrell C, Tymms P, Taylor E. Impact of early school-based screening and intervention programs for ADHD on children's outcomes and access to services: follow-up of a school-based trial at age 10 years. Arch Pediatr Adolesc Med 2010;164:462-9.
60. Pelham WE. Against the grain: a proposal for a psychosocial first approach to treating ADHD-the buffalo treatment algorithm. In: McBurnett K, Pfiffner L, eds. Attention deficit hyperactivity disorder: concepts, controversies, new directions. Informa Healthcare, 2008:301-16.
61. Singh I. Beyond polemics: Science and ethics of ADHD. Nat Rev Neurosci 2008;9:957-64.